Our Therapy Areas
We focus on developing, personalising and improving treatment for patients with central nervous system disorders, migraine, respiratory diseases, pain and cancer. We also provide over-the-counter products for consumer healthcare - available without a prescription, including well-known brands such as Sudocrem® and Infacol®
We are dedicated to addressing patients' needs, along with expanding global access to medicines and bringing benefit to wider society
We have a strong history of bringing innovative treatments to market for central nervous system disorders, such as neurological and neurodegenerative diseases, migraine and movement disorders, as well as a strong portfolio of respiratory, pain and cancer products.
Central Nervous System
Neurodegenerative conditions and movement disorders such as Multiple Sclerosis, Parkinson’s Disease, Huntington’s Disease and Tardive Dyskinesia affect every aspect of life, with even the most mundane tasks requiring great courage and effort.
There are so many challenges - physical, financial and emotional - faced every day by people and their families, living with diseases of the central nervous system.
Research in neuroscience
We are committed to understanding and studying neurodegenerative disorders so that we can find molecules that allow us to change the course of disease and offer patients and healthcare professionals a wider choice of treatments.
We are also focused on innovation to help patients safely and effectively manage pain, which can severely affect their quality of life.
Migraine can have an enormous impact on a sufferer’s work, family and social life. Getting through the day requires great effort and is filled with challenges.
It is estimated that there are currently more than a billion people with migraine on the planet, that's one in seven people.01 Unfortunately, there is currently no cure for migraine.
We surveyed more than a thousand patients with migraine in the UK, alongside thousands of others across Europe, and the results were stark. They highlight the effect migraine can have on patients, their family and their social life.
There was widespread agreement that migraine has an impact on almost every aspect of their lives, with the survey highlighting the significant burden on family and children.02
Teva's Migraine Research
Research into Migraine
Our work with patients, and our experience in this therapy area, means we are well placed to invest in extensive research into potential cures and medicines to help alleviate the many symptoms of migraine and other central nervous system disorders, to offer patients and healthcare professionals a wider choice of treatments.
5.4 million people in the UK 03 and 300 million people globally - equivalent to almost the entire population of the USA - suffer from asthma. 04 Chronic respiratory diseases, including asthma and chronic obstructive pulmonary disease (COPD), kill more than four million people every year and affect hundreds of millions more. 04 The economic and societal burden is immense.
In respiratory we are focused on developing and providing treatment options that address two major issues:
- treatment adherence and compliance (in other words patient medication-taking behaviour)
- treating asthma that remains uncontrolled - despite the use of a standard of care therapy.
Adherence is a major issue in the effective management of asthma and COPD. Moreover, many patients have multiple devices for different parts of their treatment (maintenance and rescue therapies). This adds to the complexity that patients face.
Improper inhaler use can result in increased exacerbation (acute attacks) of asthma or COPD requiring emergency care.
Research in respiratory
The focus of our global research efforts in respiratory is on breath-activated inhaled therapies for asthma and COPD, where incorrect inhaler technique and non-adherence has been shown to be associated with poor asthma control, as well as targeted biologics for uncontrolled asthma.
Smart Inhaler Technology
A key area our global research teams are focusing on is E-connectivity. Using smart inhaler technology patients may be empowered to manage their condition more effectively, and healthcare professionals could get greater insight into the patient's experience and condition to make more informed treatment decisions.
Pain is one of the most significant healthcare problems the world faces today. It impacts hundreds of millions of people across the world, profoundly affecting their quality of life and costing society countless billions of pounds in treatment along with lost productivity.
Research for pain management
Making progress on pain management options is urgently needed. We are developing a focused pipeline of new drugs and novel treatments to meet patient and societal needs in pain management.
We are bringing more relief to patients by innovating in the research of our opioid-based treatments. At the same time, we are addressing some of the key challenges associated with opioids - their abuse and misuse.
When a patient is told they have cancer, their world – and the worlds of their families and loved ones – is turned upside down. In addition to coping with the illness itself, the side-effects of the prescribed treatment can also be harrowing and difficult. Yet, thankfully, there have been tremendous advancements in care in recent years.
Cancer impacts hundreds of millions of people across the world, profoundly affecting their quality of life and costing society countless billions of pounds in treatment.
Research in oncology
We invest in extensive research into potential cures and medicines to help alleviate the many symptoms of cancer, to offer patients and healthcare professionals a wider choice of treatments.
Our consumer healthcare range includes over-the-counter products available without a prescription. It features well-known brands in the baby care sector Sudocrem® and Infacol®, and recently introduced sexual health medicine Liberize™ (sildenafil), as well as age-old traditional remedies such as MacKENZIES® smelling salts and Yeast Vite.
Applying expertise, innovation and technology to improve health
We invest significantly into research and development to help our scientists effectively bring medicines to market so that our product portfolio addresses the changing needs and challenges of healthcare. It is this research that forms the engine for growth and development, not only for our company, but as part of our aspiration to improve health.
We are exploring new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Our expertise spans drug development and product delivery to the patient, monitoring and support services.
We have one of the largest generics research and development teams in the industry, allowing us to research generic products including complex generics and biosimilars, and to explore genuine advances on existing therapies by formulating, delivering or using them in a novel way.
Innovation around existing molecules
Part of our focus in generics research is developing new therapeutic entities, based on known and approved chemical molecules. These molecules are reformulated, repurposed or re-engineered to be delivered in a new way to address specific, unmet patient needs. It has the potential to deliver a range of new treatment options, reduce cost of treatment and reduce the financial burden to the healthcare system.
Investing in both original biologic medicines and in biosimilars to help patients around the world
Biopharmaceutical therapies have transformed the way many diseases are treated; they have, and continue to, revolutionise treatment outcomes for patients across a broad range of conditions
Teva is working hard to realise the full promise of these remarkable medicines. As the equivalent to generics for name brand biologics, biosimilars offer patients and healthcare systems access to high cost medicines at a more affordable level.
Back to contents.
Migraine Trust https://migrainetrust.org/understand-migraine/what-do-we-currently-know-about-migraine/ - Accessed July 2023
Back to contents.
Teva UK Data on File 214, September 2020*. [*Independent data collection was conducted at the request of and with financial support of Teva]
Back to contents.
Asthma and Lung UK https://www.asthmaandlung.org.uk/conditions/asthma/what-asthma#:~:text=Asthma%20is%20a%20very%20common,one%20in%20every%2011%20children. Accessed July 2023
Back to contents.
World Health Organisation: Global surveillance prevention and control of chronic respiratory diseases.